Related Experiment Video
Updated: Nov 24, 2025
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Circular dumbbell miR-34a-3p and -5p suppresses pancreatic tumor cell-induced angiogenesis and activates macrophages
Manu Gnanamony1, Lusine Demirkhanyan2, Liang Ge3
1Department of Pediatrics, University of Illinois College of Medicine Peoria, Peoria, IL 61605, USA.
Abstract:
Angiogenesis is a tightly regulated biological process by which new blood vessels are formed from pre-existing blood vessels. This process is also critical in diseases such as cancer. Therefore, angiogenesis has been explored as a drug target for cancer therapy. The future of effective anti-angiogenic therapy lies in the intelligent combination of multiple targeting agents with novel modes of delivery to maximize therapeutic effects. Therefore, a novel approach is proposed that utilizes dumbbell RNA (dbRNA) to target pathological angiogenesis by simultaneously targeting multiple molecules and processes that contribute to angiogenesis. In the present study, a plasmid expressing miR-34a-3p and -5p dbRNA (db34a) was constructed using the permuted intron-exon method. A simple protocol to purify dbRNA from bacterial culture with high purity was also developed by modification of the RNASwift method. To test the efficacy of db34a, pancreatic cancer cell lines PANC-1 and MIA PaCa-2 were used. Functional validation of the effect of db34a on angiogenesis was performed on human umbilical vein endothelial cells using a tube formation assay, in which cells transfected with db34a exhibited a significant reduction in tube formation compared with cells transfected with scrambled dbRNA. These results were further validated in vivo using a zebrafish angiogenesis model. In conclusion, the present study demonstrates an approach for blocking angiogenesis using db34a. The data also show that this approach may be used to targeting multiple molecules and pathways.
Insights
Researchers developed a novel dumbbell RNA (dbRNA) therapy to block pathological angiogenesis, crucial in cancer. This approach targets multiple pathways, showing significant promise for effective anti-angiogenic cancer treatments.
Area of Science:
- Molecular Biology
- Cancer Biology
- Biotechnology
Background:
- Angiogenesis, the formation of new blood vessels, is essential for development but also critical in cancer progression.
- Targeting angiogenesis is a key strategy in cancer therapy, but effective treatments require novel approaches.
- Combining multiple targeting agents offers a promising avenue for enhanced anti-angiogenic therapy.
Purpose of the Study:
- To develop and validate a novel dumbbell RNA (dbRNA) therapeutic strategy targeting pathological angiogenesis.
- To investigate the efficacy of a specific dbRNA construct (db34a) targeting miR-34a-3p and -5p for anti-angiogenic effects.
- To establish a robust method for dbRNA purification and functional assessment.
Main Methods:
- Construction of a plasmid expressing miR-34a-3p and -5p dbRNA (db34a) using the permuted intron-exon method.
- Development of a modified RNASwift protocol for high-purity dbRNA purification from bacterial cultures.
- In vitro validation using pancreatic cancer cell lines (PANC-1, MIA PaCa-2) and human umbilical vein endothelial cells (tube formation assay).
- In vivo validation using a zebrafish angiogenesis model.
Main Results:
- A plasmid expressing db34a was successfully constructed and a high-purity purification protocol was established.
- db34a significantly inhibited tube formation in human umbilical vein endothelial cells, indicating anti-angiogenic activity.
- In vivo studies in zebrafish confirmed the anti-angiogenic potential of db34a.
Conclusions:
- The study demonstrates a novel approach for blocking pathological angiogenesis using db34a.
- This dbRNA-based strategy effectively targets multiple molecules and pathways involved in angiogenesis.
- db34a represents a promising therapeutic candidate for anti-angiogenic cancer therapy.
